SHANGHAI – Beijing-based Beigene Co. Ltd. has shared positive phase I results for BGB-3111, a targeted small-molecule BTK inhibitor to treat B-cell malignancies that Beigene execs believe has the potential to become best in class, beating out ibrutinib (Imbruvica, Pharmacyclics Inc./Johnson & Johnson), the only BTK inhibitor currently on the market in the U.S. and Europe.